DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

DISCO Pharmaceuticals United States of America United Kingdom California New York

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets.Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer.Experienced team of individuals with expertise in surface proteomics and oncology from academia, biotech and pharma, led by CEO Roman Thomas.Leading biopharma executives Dieter Weinand (previously CEO at Bayer Pharmaceuticals) and Carsten Reinhardt (CDO at Immatics), join the DISCO Board of Directors as Chairman and Independent Director, respectively.View original content:https://www.prnewswire.co.uk/news-releases/disco-pharmaceuticals-launches-as-the-surfaceome-company-with-eur-20-million-in-seed-financing-302035546.html

@ prnewswire.co.uk